Various strategies might be considered to improve current chemotherapy regimens, such as simultaneous use of chemotherapy and antiviral agents, addition of a proteasome inhibitor or other agent to overcome NFκB-induced chemotherapy resistance [35], [36], or p53 inactivation in tumor cells [37]. The gene discussed is NFKB1; the disease is neoplasm.